Previous studies showed a synergistic effect of melatonin and deprenyl against dopamine (DA) autoxidation in vitro. Since oxidative stress is implicated in Parkinson's disease (PD), we explored the effects of melatonin plus deprenyl administration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD in C57/Bl6 mice. Melatonin, but not deprenyl prevents the inhibition of mitochondrial complex I and the oxidative damage in nigrostriatal neurons induced by MPTP. With the dose used deprenyl recovers 50% DA levels and tyrosine hydroxylase activity depressed by the neurotoxin, normalizing locomotor activity of mice. Melatonin, which was unable to counteract MPTP-induced DA depletion and inhibition of tyrosine hydroxylase activity, potentiates the effect of deprenyl on catecholamine turnover and mice ambulatory activity. These results suggest a dissociation of complex I inhibition from DA depletion in this model of Parkinson's disease. The data also support that a combination of melatonin, which improves mitochondrial electron transport chain and reduces oxidative damage, and deprenyl, which promotes the specific function of the rescued neurons, i.e. DA turnover, may be a promising strategy for the treatment of PD.
Introduction
Parkinson's disease (PD) is a disorder characterized by the degeneration of nigrostriatal dopaminergic neurons [11] . Recent advances suggest that dysfunction of the mitochondrial respiration [43] and generation of free radicals by oxidative catabolism of dopamine (DA) [17] are important mediators of neuronal death in PD. The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) recreates a PD-like model in both rodents and primates [25] . MPTP neurotoxicity depends on the monoamine oxidase B(MAO B)-catalyzed production of MPP + , which is taken up selectively by dopaminergic neurons and concentrated into the mitochondria. MPP + inhibits the activity of complex I of the electron transport chain [23] leading to production of reactive oxygen species, loss of the mitochondrial membrane potential and ATP production, and neuronal death [13] . MPP + also induces DA efflux [50] , increasing DA autoxidation and oxidative damage [15] .
Deprenyl and melatonin show neuroprotective properties. Deprenyl, a MAO B inhibitor, blocks MPP + formation from MPTP in the glial cells protecting neurons against the devastating effect of the neurotoxin [26] . Other actions of deprenyl such as the increase in superoxide dismutase activity [34] , the reduction of free radical formation [32] , and the antiapoptotic activity [55] , are also involved in its neuroprotective effect. Melatonin is a strong scavenger of free radicals [46, 48] and regulates the activity and expression of antioxidant enzymes [9, 37] . Melatonin reportedly protects cells, tissues and organs against oxidative damage caused by various free radical generating agents [5, 16, 17] . Melatonin also protects the brain against oxidative damage [3, 47] . In the model of MPTP-induced PD in mice, the indoleamine rescues tyrosine hydroxylase (TH) positive neurons, reduces nigrostriatal lipid peroxidation (LPO) [3, 4] , and protects brain cells from DNA fragmentation and apoptosis [44] . In vitro, melatonin rescues DA neurons from MPP + -induced cell death [28] , and protects mitochondrial dysfunction produced by the neurotoxin [1] . Recently, it was reported that melatonin protects mitochondria against oxidative stress, increasing the activity of complex I and IV and ATP production, and decreasing mitochondrial hydroperoxides [5, 37, 38] .
These data led us to explore the in vivo effects of melatonin and deprenyl in MPTP-induced parkinsonian mouse model. Mice were treated with MPTP and 24 h later DA turnover, tyrosine hydroxylase activity, lipid peroxidation and mitochondrial complex I activity were determined in nigrostriatal tissue. Locomotor activity was also measured before and after MPTP treatment. To study the neuroprotective effects of melatonin and deprenyl, the drugs were administered alone or in combination 30 min before the neurotoxin, followed by the same determinations 24 h later.
Materials and methods

Chemicals
All reagents used were of the highest purity available. Deoxyepinephrine (DE), dopamine (DA), 3,4-dihydroxybenzylamine (DHBA), 3,4-dihydroxyphenyl acetic acid (DOPAC), homovanilic acid (HVA), 3-methoxytyramine (3MT), 5-hydroxytryptamine (5HT), 5-hydroxyindole-3-acetic acid (5HIAA), N-acetyl-5-methoxytryptamine (melatonin), EDTA, m-hydroxybenzylhydrazyne dichloride (NDS-1015), 6,7-dimethyl-5,6,7,8-tetrahydropterine monohydrochloride (DTPH 4 ), 3,4-dihydroxyphenylalanine (l-DOPA), l-tyrosine, antimycin A, NADH, decylubiquinone (DB), potassium cyanide (KCN), citric acid, sodium octyl sulfate, and 2-mercapto-ethanol, were purchased from Sigma-Aldrich (Madrid, Spain). HPLC-grade methanol, perchloric acid, sodium acetate, SO 3 Na 2 , S 2 O 5 Na, Tris and alumina were obtained from PANREAC (Barcelona, Spain). MPTP and deprenyl were purchased from RBI. All remained chemicals were of analytical grade and were purchased from Sigma-Aldrich (Spain). Solutions were prepared with MILLI-RO/Q grade water.
Animals
Adult male C57/BL6 mice weighing 28-30 g (3-4-month old), were obtained from the Granada's University facility and housed in clear plastic cages maintained at 22 ± 1 • C, and 40% humidity, with 12 h on, 12 h off light-dark cycles (lights on at 08:00 h). Mice were feed with tap water and a standard diet ad libitum. All experiments were carried out according to the Spanish Government Guide and the European Community Guide for animal care. Special care was taken to avoid environmental stress before and during the experiments.
Experimental protocol
MPTP and deprenyl were dissolved in 0.9% saline, and melatonin was dissolved in 2.5% ethanol/saline. These solutions were prepared immediately before their injection and the unused portions were discarded at the end of each session. MPTP was administered subcutaneously in the dorsal neck, and deprenyl and melatonin were intraperitoneally injected.
The study was carried out in groups of 6-8 animals per treatment. Each animal received one injection of MPTP (15 mg/kg) 30 min after the administration of melatonin (5 or 10 mg/kg), deprenyl (0.37 mg/kg), deprenyl + melatonin (0.37 mg/kg of deprenyl plus 5 or 10 mg/kg of melatonin), or vehicle (control). Twenty-four hours after treatment, animals were tested for the locomotor activity or sacrificed by cervical dislocation for biochemical analysis. The brains were rapidly removed and immediately placed on an ice-cooled plate for dissection. Striata and substantia nigra were dissected out, and the substantia nigra was further dissected out by punch of a 2 mm diameter. Tissues were stored at −80 • C for subsequent catecholamine analysis and LPO, or immediately used for TH activity assay or mitochondria isolation and for complex I activity measurements.
Locomotor activity measurement
Locomotor activity was tested in a sound-isolated room with artificial light and constant temperature. This test room was used only for this purpose. The ambulatory activity of each animal was measured between 12:00 and 18:00 h. using Grid actimeter cage (50 cm × 27 cm × 24 cm) (Cibertec, Madrid, Spain). The cage floor was made up of 40 evenly spaced stainless steel bars. The odd bars were earthed whereas the even bars were active and wired in sets of four. The electronic bridges that the animal made or broke as it moved were detected and counted by an electronic unit. The number of counts was an indicator of ambulatory activity and was automatically recorded by a LI 3333 printer every 90 s. The animal was allowed to explore the activity cage for 150 min and then, the locomotor activity was recorded for a total of 180 min and presented as the accumulated number of counts.
Catecholamine assay
For catecholamine assay, frozen striata were rapidly thawed, weighed and homogenized in ice-cold 0.2 M perchloric acid containing 1 mM EDTA-Na 4 and 0.4 mM S 2 O 5 Na to prevent DA autoxidation. The homogenates were centrifuged at 15,000 × g for 20 min at 4 • C and the supernatant were passed through a 0.2 m filter and analyzed by HPLC-ED [32] . Separations were done in a C-18 reversed-phase 5 m sphere analytical column. The potential applied was set at +0.65 V using a glassy carbon electrode versus an Ag/AgCl reference electrode. The mobil phase consisted of 50 mM sodium acetate, 50 mM citric acid, 0.4 mM sodium octyl sulfate, 1.1 mM n-dibutyl amine, 0.15 mM EDTA-Na 2 and 5% (v/v) methanol/water. The solution was filtered through a 0.45 m filter and degassed before use. Analyses were done at a flow rate of 1 ml/min at room temperature. The concentrations of DA, DOPAC, HVA, 3MT, 5HT, and 5HIAA in the samples were calculated using DHBA and DE as internal standards and a calibration curve obtained from the corresponding standards injected in the HPLC system. The retention times were 4.9 min for DHBA, 6 min for DOPAC, 7.7 min for DA, 8.5 min for DE, 11.8 min for 5HIAA, 14.8 min for HVA, 19.9 for 3MT, and 23.9 min for 5HT. Calibration curves for those compounds were linear between 10 and 30 g/l for DOPAC, 5HIAA, HVA, 3MT, and 5HT, and 50-150 g/l for DA, with correlation coefficients of 0.97-0.99. Monoamines and their metabolites in the striatal samples could be easily identified comparing their retention times and electrochemical characteristics with those of their corresponding standards, and their concentrations were expressed in ng/mg wet striatum.
Tyrosine hydroxylase assay
TH activity in striata and substantia nigra was determined as the rate of the enzyme-catalyzed tyrosine hydroxylation to 3,4-dihydroxyphenylalanine (l-DOPA) in the presence of cofactor and an l-DOPA decarboxylase inhibitor [12] . Tissues were weighted and homogenized in ice-cold 0.25 M sucrose, and then the following solution was added: 300 l of 1 M sodium acetate buffer pH 6, 100 l of 2.5 mM NDS-1015 and 1 ml of 1 mM l-tyrosine. After preincubation at 37 • C for 4 min, the reaction was started by the addition of 100 l of 10 mM DTPH 4 dissolved in 1 M 2-mercaptoethanol. Incubation was carried out at 37 • C for 30 min in a shuttle water thermostat, and 200 l of 0.7 M perchloric acid was added to stop the reaction. After the addition of DHBA as internal standard, the samples were centrifuged at 16,000 × g for 15 mm at 4 • C. The l-DOPA formed and the internal standard were extracted with alumina, and the concentration of l-DOPA was estimated by HPLC-ED. The mobil phase consisted of 80 mM citric acid, 56 mM sodium acetate, 2 mM EDTA-Na 2 and 0.1 mM sodium octyl sulphate and 5% (v/v) methanol/water. The solution was filtered through a 0.45 m filter and degassed before use. Analyses were done at a flow rate of 1 ml/min at room temperature. The concentration of l-DOPA in the samples was calculated using DHBA as internal standard and a calibration curve obtained from the corresponding standards injected in the HPLC system. The retention times were 2.7 min for DOPA and 4.5 min for DHBA. Calibration curve for l-DOPA showed linearity between 25 and 150 g/l, with correlation coefficients of 0.96-0.99. The activity of TH was expressed as pg l-DOPA/min/mg wet tissue.
Lipid peroxidation assay
MDA and 4-HNE, the final products of LPO, were measured by a colorimetric assay using the Bioxytech LPO-586 colorimetric kit assay (OXIS Res, Portland, OR, USA) [19] . Briefly, tissue samples were homogenized in 20 volumes (w/v) of ice-cold 20 mM Tris-HCl buffer, pH 7.4. The homogenates were centrifuged at 1000 × g for 10 min at 4 • C. Aliquots of the supernatant were incubated at 45 • C for 40 min in the presence of N-methyl-2-phenylindole/methanol and methanesulfonic acid. The reaction was stopped by chilling samples on ice and centrifuged at 12,000 × g for 5 min at 4 • C. The absorbance in the supernatant was estimated spectrophotometrically at 586 nm, and concentrations were calculated from a standard curve made with known amounts of MDA and 4-HNE.
Complex I (NADH: ubiquinone oxidoreductase) assay
Mitochondria were prepared by differential centrifugation followed by Percoll purification [27] . Briefly, striata from four mice were excised, weighed, washed with 0.25 M sucrose, and homogenized (1/8, w/v) in a medium containing 250 mM mannitol, 0.5 mM EGTA, 0.1% (w/v) BSA, 5 mM Hepes/KOH, pH 7.4 at 4 • C. The homogenate was centrifuged for 5 min at 600 × g and the supernatant was centrifuged at 10,300 × g for 10 min. Intact, purified mitochondria were isolated using Percoll to remove contaminating organelles and broken mitochondria. The pellet (mitochondrial fraction) was resuspended in 200 l of the homogenizing medium supplemented with 800 l of 30% Percoll in 225 mM mannitol, 1 mM EGTA, 25 mM Hepes, 0.1% BSA. This mixture was centrifuged at 95,000 × g in a Beckman TLA 100.4 rotor for 30 min. The fraction with a density of 1.052-1.075 g/ml was collected and washed twice with the homogenizing buffer at 6300 × g for 10 min to remove the Percoll. The mitochondrial pellet obtained was resuspended in 0.25 M sucrose, 50 mM KH 2 PO 4 , pH 7.4, freeze-thawed twice to prepare submitochondrial particles, and used for estimating the activity of complex I. Protein content was determined by the method of Lowry et al. [36] .
NMDH: ubiquinone oxidoreductase (complex I) activity was assayed by monitoring the oxidation of NADH to NM) by DB, a synthetic water-soluble analog of ubiquinone (coenzyme Q) [20] . An aliquot of the submitochondrial suspension (0.5 mg protein/ml, final concentration) was added to the reaction mixture (final incubation volume 700 l) contained 0.25 M sucrose, 50 mM KH 2 PO 4 , pH 7.4, 1 mM KCN, 10 g/ml antimycin A and 50 M DB. After preincubation for 3 min at 25 • C, the reaction was initiated by the addition of NADH (100 M, final concentration) and the rate of decrease in the absorbance was monitored at 340 nm for 1.5 min. That NADH oxidase activity measured with this method corresponds to complex I was further confirmed since incubation in the presence of 1 M rotenone completely abolished the enzyme activity. The complex I activity was expressed as nmol of NADH oxidized/min/mg protein.
Statistical analyses
All data are expressed as the means ± S.E.M. One-way analysis of variance (ANOVA I) followed by StudentNeuman-Keuls multiple comparison test were used for statistical purposes. A value P < 0.05 was considered significant. Melatonin alone had no effect, while deprenyl totally counteracted locomotor activity of MPTP-treated mice. Combination of 10 mg/kg melatonin plus deprenyl further increase the ambulatory activity altered by MPTP. Data represent the mean ± S.E.M. of cumulative counts of eight animals per group analyzed individually. * * P < 0.001 vs. untreated (control) animals; ++ P < 0.001 vs. MPTP-treated animals; # P < 0.01 vs. MPTP + deprenyl treated mice.
Results
Locomotor activity
The ambulatory activity of the mice was significantly reduced after MPTP treatment compared untreated mice (5754 ± 535 versus 1360 ± 528 cumulative counts, P < 0.001) (Fig. 1) . Deprenyl but not melatonin recovered the locomotor activity to control values (P < 0.001). However, administration of 10 mg/kg melatonin fur- ther improved the activity of mice induced by deprenyl (P < 0.01).
Melatonin plus deprenyl effect on striatal catecholamines
Administration of MPTP to C57/Bl6 mice produced a typical dose-dependent decrease in striatal DA content and DA metabolites (Table 1) . No changes were found in 5HT and its metabolite 5HIAA after MPTP treatment. These changes were followed by a significant increase in DOPAC/DA ratio, an indicator of DA catabolism. Compared with controls, the dose of 15 mg/kg of MPTP produced a significant decrease in DA content (4.65 ± 0.9 ng/mg versus 12.9 ± 0.4 ng/mg striatum, P < 0.001) and a significant increase in DOPAC/DA ratio (0.10 ± 0.008 versus 0.06 ± 0.006, P < 0.001). Thus, we used this dose of MPTP for the following experiments. Table 2 shows the dose-dependent effects of deprenyl on the MPTP-induced changes in striatal catecholamine content. At the dose of 5 mg/kg deprenyl restored both the DA content and the DOPAC/DA ratio in mice striatum, without affecting the serotonergic system. With 0.37 mg/kg deprenyl partially recovered DA content (7.47 ± 0.63 ng/mg versus 4.18 ± 0.96 ng/mg striatum, P < 0.001) and reduced DOPAC/DA ratio (0.08 ± 0.008 versus 0.11 ± 0.008, P < 0.01).
The next experiment was designed to test whether melatonin could counteract the MPTP-induced striatal catecholamine changes. Animals were treated with 15 mg/kg MPTP, 0.37 mg/kg deprenyl, and/or 5 and 10 mg/kg melatonin. The results showed that melatonin alone was unable to modify the MPTP-induced changes in striatal content of DA and its metabolites (Fig. 2) . The DOPAC/DA ratio was also unchanged after melatonin administration (data not shown). Interestingly, melatonin administration enhanced the effects of deprenyl, and when both compounds were simultaneously injected, the levels of DA, DA metabolites and DOPAC/DA ratio reached control values. Thus, 5 mg/kg melatonin plus 0.37 mg/kg deprenyl produced a higher increase in striatal DA content than deprenyl alone (P < 0.01). In any case, melatonin did not modify significantly the levels of 5HT or 5HIAA. 
Tyrosine hydroxylase activity
To assess the effects of deprenyl and melatonin on TH activity, a group of animals was injected with 15 mg/kg MPTP, 0.37 mg/kg deprenyl, and/or 5 and 10 mg/kg melatonin. The dose of deprenyl used counteracted the MPTP-induced decrease of TH activity in substantia nigra but not in Fig. 2 . Effects of melatonin and/or deprenyl on striatal catecholamine content in MPTP-treated mice. Mice were treated with the same protocol as Fig. 1 . Melatonin was unable to restore DA or DA metabolites content but potentiated the effect of deprenyl on these parameters. No changes were found in 5HT or 5HIAA after treatments. Data represent the mean ± S.E.M. of 6-8 animals assayed in duplicate * P < 0.001 and * * P < 0.001 vs. untreated (control) animals; + P < 0.01 and ++ P < 0.001 vs. MPTP-treated animals; # P < 0.01 and ## P < 0.001 vs. MPTP + deprenyl treated mice. striatum (Fig. 3) . Now, 5 mg/kg melatonin potentiated the effect of deprenyl, producing a higher effect on TH activity in both substantia nigra and striatum compared with animals treated with deprenyl alone (P < 0.01). The synergistic effect of melatonin on deprenyl action recovered TH activity in striatum of MPTP-treated mice to control values. Fig. 3 . Histrograms showing tyrosine hydroxylase activity in the striatum and substantia nigra of mice Animals were treated as in Fig. 1 . Deprenyl partially restored TH activity inhibited by MPTP. Whereas melatonin was unable to modify TH activity, it significantly potentiated the effect of deprenyl administration, and the simultaneous administration of these drugs counteracted the MPTP effects. Data represent the mean ± S.E.M. of 6-8 animals assayed in duplicate. * * P < 0.001 vs. untreated (control) animals; + P < 0.01 and ++ P < 0.00 vs. MPTP-treated animals; # P < 0.01 and ## P < 0.001 vs. MPTP + deprenyl treated mice.
Lipid peroxidation
To evaluate the degree of oxidative stress, the levels of striatal LPO in MPTP-treated mice were assessed. The data show that 15 mg/kg MPTP significantly increased LPO compared to control animals (0.95 ± 0.04 versus 0.63 ± 0.01 nmol MDA+4HNA/mg striatum, P < 0.001) (Fig. 4) . Administration of 5 mg/kg melatonin was enough to counteract the effect of MPTP, decreasing LPO to control values (0.7 ± 0.05 nmol MDA + 4HNA/mg striatum, P < 0.01), whereas 10 mg/kg melatonin significantly decrease LPO below control levels (0.54 ± 0.002 nmol MDA + 4HNA/mg striatum, P < 0.01). The administration of deprenyl alone was without effect on LPO, and simultaneous administration of melatonin plus deprenyl caused similar protection to that observed with melatonin alone.
Complex I
To evaluate further the differences in the actions of deprenyl and melatonin in MPTP-induced nigrostriatal damage, the activity of the complex I was assayed in mitochondria obtained from striatum. As expected, 15 mg/kg MPTP induced a significant decrease in complex I activity (8.66 ± 0.17 nmol/mg protein/min versus 14.06±0.25 nmol/mg protein/min P < 0.001) (Fig. 5) . The lowest dose of melatonin used, 5 mg/kg, counteracted the effect of MPTP, restoring the control activity of the enzyme (13.03 ± 0.45 nmol/min/mg protein, P < 0.001). Treatment with deprenyl was unable to counteract any effect of MPTP on complex I activity, and the administration of deprenyl to melatonin-treated animals did not modify the effects of the indoleamine alone. Fig. 1 . MPTP induced oxidative stress as by the increase in LPO. Melatonin treatment decreased LPO in a dose-dependent effect, whereas deprenyl had no effect. Simultaneous injection of deprenyl plus melatonin did not change the effect of melatonin alone. Data represent the mean ± S.E.M. of 6-8 animals assayed in duplicate. * P < 0.01 and * * P < 0.001 vs. untreated (control) animals; + P < 0.001 and ++ P < 0.001 vs. MPTP-treated animals; # P < 0.01 and ## P < 0.001 vs. MPTP + deprenyl treated mice.
Discussion
The results of this study show that melatonin and deprenyl collaborate to prevent nigrostriatal pathway damage against MPTP. Melatonin and deprenyl act on different aspects of MPTP-induced damage. Whereas melatonin maintains mitochondrial respiration and reduces oxidative stress, deprenyl partially prevents DA turnover and TH activity changes, avoiding locomotor activity reduction. Nevertheless, the presence of melatonin in deprenyl-treated animals led to a normal TH activity and DA turnover, which may explain the ambulatory behavior improved after the dual treatment. It is interesting to note that melatonin reverses complex I inhibition and suppresses LPO but fails to prevent DA depletion and TH activity reduction due to MPTP. This discovery does not support the hypothesis that inhibition of complex I leads to DA depletion and nigral degeneration in this model of Parkinsonism. In fact, it should be noted that MPTP-induced complex I inhibition is not limited to the damaged brain region of the dopaminergic nigrostriatal neurons, but a more general mechanism [43] .
Parkinson's disease is not a disease entity caused by only one pathogenetic factor. The substantia nigra of PD patients have dramatically decreased levels of GSH, the main mito- Fig. 5 . Effect of on MPTP-induced mitochondrial complex I inhibition in mice striatum. Mice were treated following the same protocol as in Fig. 1 . The lowest dose of melatonin used, i.e. 5 mg/kg, was able to counteract the decrease in complex I activity induced by MPTP, whereas deprenyl had no effect. Data represent the mean±S.E.M. of three independent experiments assayed in duplicate of pooled striate from six mice each. * * P < 0.001 vs. untreated (control) animals; ++ P < 0.001 vs. MPTP-treated animals; ## P < 0.001 vs. MPTP + deprenyl treated mice.
chondrial antioxidant. The reduction in mitochondrial GSH increases oxidative stress, decreases electron transport chain activity and ATP production, and opens the mitochondrial permeability transition pore, inducing apoptosis [13, 30] . The participation of mitochondria on the pathophysiology of PD was recently sustained by rotenone administration, a specific inhibitor of mitochondrial complex I, that reproduced the anatomical, neurochemical and neuropathological features of PD [10] . Oxidative stress has also received increasing attention in the MPT model of PD, because the neurotoxin causes inhibition of mitochondrial respiration and increases oxidative metabolism of DA, yielding oxygen free radicals including hydrogen peroxide and hydroxyl radical [13] . Therefore, mitochondrial oxidative damage is a main pathophysiological feature in PD including the model of MPTP-induced PD here studied. and thus, free radical scavengers should be of great interest protecting dopaminergic neurons from apoptosis induced by mitochondrial oxidative damage and/or complex I inhibitors [51] .
Antioxidant strategies may be classified into two categories. The first involves the use of antioxidants including some vitamins and nutrients and the second involves modifications of endogenous antioxidant enzymes. The use of vitamins in oxidative stress-related neurodegenerative diseases has poor result due to the limited bioavailability and efficiency of the drugs by kinetic reasons [34] . Thus, it is necessary that use of antioxidants that penetrates the bloodbrain barrier such as melatonin [24] . Melatonin displays important antioxidant properties based on its free radical scavenger ability [46, 48, 52, 53] and, in contrast to conventional antioxidants, rapidly crosses the blood-brain barrier after systemic administration and reaches every neuronal compartment [41] . Melatonin also regulates the expression and activity of the redox enzymes [9, 16] . Deprenyl shares with melatonin common features such as neuroprotective and antioxidant effects, and we recently reported a synergistic effects between both compounds against DA autoxidation in vitro [32] . Thus, we asked if these compounds may also collaborate in vivo against MPTP-induced neuronal damage.
Deprenyl, an inhibitor of MAO B, blocks MPTP metabolization protecting neurons against the devastating effect of MPP + . However, deprenyl protection against MPTP-induced PD does not only depend on the inhibition of MAO B activity [40] . The neuroprotection by deprenyl has been associated with several intracellular mechanisms including inhibition of DA uptake, increase of mRNA trophic factors, and increase TH enzyme [40, 49] . Other actions such as an antioxidant role, enhancement of the antioxidant enzymes superoxide dismutase and catalase, and preservation of mitochondrial membrane potential are directly related with the neuroprotective actions of deprenyl [32, 34] . To study whether melatonin potentiates the effects of deprenyl, a low dose of the drug was used. At the dose of 0.37 mg/kg, deprenyl completely counteracts locomotor activity depressed by MPTP, but only antagonizes the 50% of DA levels and TH activity. This dose of deprenyl did not modified MPTP-dependent oxidative stress and mitochondrial damage.
Although it was showed that melatonin does not affect MPTP-induced changes in DA turnover and locomotor activity [29] , we found that its combination with deprenyl results in a full prevention of TH activity and striatal DA content reduction, which may account for the further increase of locomotor behavior. These results may reflect a modulation of striatal DA turnover by melatonin [33] . Anyway, the synergy between melatonin and deprenyl may depend on several factors. One, the protective effect of both compounds against DA autoxidation [32] , since DA accumulates extraneuronally mainly due to a massive DA efflux induced by the MPP + [50] plus the deprenyl-dependent DA uptake inhibition [26] . In addition, deprenyl-induced TH enzyme may be favored by the increase of TH activity due to melatonin [7, 31] . A third factor involved in melatonin-deprenyl synergy come from their effect to enhance gene expression of glial cell line-derived neurotrophic factor [54] , which in turn protects nigrostriatal pathway against MPTP [45] .
The effects of melatonin against MPTP-dependent oxidative stress and mitochondrial damage were not reproduced by deprenyl treatment. The mode of MPTP-induced cell death involves binding of its endogenous metabolite, MPP + at the same site as rotenone, the specific inhibitor of complex I [23] , and rotenone administration reproduces PD [10] . MPP + not only blocks the mitochondrial ATP production leading to energy failure, but causes increase of both superoxide anion and hydrogen peroxide [21] , depleting the cell from GSH. The loss of GSH also accounts for the decrease of complex I activity [8] . Since LPO, a reliable index of oxidative damage induced by MPTP in striatal neurons, was counteracted by melatonin, the antioxidant role of the indoleamine seems be involved in its neuroprotective action. In fact, melatonin attenuates MPP + -induced neurodegeneration and glutathionc impairment in the nigrostriatal dopaminergic pathway [14] , protects against MPTP-induced oxidative stress and apoptosis [4, 29, 31, 44] by a mechanism partially involving hydroxyl radical scavenging [35] , counteracts MPTP-induced inhibition of complex I [1] , reverts 6-OHDA-induced Parkinsonism [17] , and increases mitochondrial GSH content [37] . Besides these mechanisms, it has been recently reported that melatonin reverts 6-OHDA-induced striatal neurochemical alterations in association with striatal D 1 /D 2 DA receptor modification [6] . These data agree with he interaction between melatonin and striatal D 1 /D 2 receptors elsewhere reported with electrophysiological approaches [18] . Experiments in vivo and in vitro have shown that melatonin promotes mitochondrial phosphorylation and ATP synthesis interacting with the electron transport chain complexes I and IV [5, [37] [38] [39] . These effects are related to the antioxidant role of melatonin, since it scavenges hydrogen peroxide [53] and increases mitochondrial GSH levels, counteracting the oxidative stress-induced mitochondrial damage [37] . These data, with those reporting an effect of melatonin on mitochondrial inner membrane fluidity [22] , further support that mitochondria are an important target for melatonin action [2, 5] .
The evidence suggests that mitochondria play a part in the events leading to death of dopaminergic neurons in PD. However, our data show that inhibition of mitochondrial complex I is not the primary mechanism by which MPP + preferentially affects behavior and kills dopaminergic neurons in the acute model of MPTP-induced PD [42] . Thus, our previous reports showing that melatonin rescues nigrostriatal TH positive neurons from MPTP [4, 44] should reflect a protection by melatonin against oxidative damage-induced cell death, and it is independent of the mitochondrial damage. Anyway, the production of free radicals within mitochondria and from DA metabolism can be enhanced by a pre-existing mitochondrial defect that in turn may increase oxidative phosphorylation dysfunction [43] . Therefore, continued generation of free radicals and ATP deficit may participate in the cell death of chronic PD. Whether melatonin breaks this vicious circle, counteracting complex I deficiency, should be assessed in long-term studies. We can conclude that melatonin protects striatal mitochondria against MPTP, and potentiates the effect of deprenyl on DA turnover. Since mitochondrial targeting is now considered a primary objective in the therapeutic approaches of antioxidants that penetrate the blood-brain barrier [24] , the use of melatonin plus deprenyl should be considered of great interest in the treatment of Parkinson's disease.
